C5b-9 staining correlates with clinical and tumor stage in gastric adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 24, Issue 7, 2016, Pages 470-475

  Chen, Jian ^a   Yang, Wei Jun ^b   Sun, Hai Jian ^a   Yang, Xia ^a   Wu, Yu Zhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b First People's Hospital of Guiyang   (China)

Author keywords

complement 5b 9; human gastric adenocarcinoma; immunohistochemistry; tissue microarray

Indexed keywords

COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PARENCHYMA; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; UPREGULATION; ADENOCARCINOMA; EVALUATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; PROCEDURES; STAINING; STOMACH NEOPLASMS;

ADENOCARCINOMA; COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; STAINING AND LABELING; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84983336764     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000218     Document Type: Article

References (32)

1. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. Lancet. 2009; 374: 470 -490.
2. Chung HW, Lim JB. Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2014; 20: 1667-1680.
3. Oba K, Paoletti X, Bang YJ, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data metaanalysis. Eur J Cancer. 2013; 49: 1565-1577.
4. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med. 2014; 16: 1-18.
5. Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011; 51: 45-60.
6. Swe PM, Reynolds SL, Fischer K. Parasitic scabies mites and associated bacteria joining forces against host complement defence. Parasite Immunol. 2014; 36: 585-593.
7. Anquetil F, Clavel C, Offer G, et al. IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- And complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies. J Immunol. 2015; 194: 1-11.
8. Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015; 26: ASN.2014101000.
9. Danobeitia JS, Djamali A, Fernandez LA. The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair. 2014; 7: 1-11.
10. Pio R, Ajona D, Lambris JD. Complement inhibition in cancer therapy. Semin Immunol. 2013; 25: 54-64.
11. Ostrand-Rosenberg S. Cancer and complement. Nat Biotechnol. 2008; 26: 1348-1349.
12. te Velde ER, Berrens L, Zegers BJ, et al. Acute phase reactants and complement components as indicators of recurrence in human cervical cancer. Eur J Cancer. 1979; 15: 893-899.
13. Arsenakis M, Georgiou GM, Welsh JK, et al. AG-4 complementfixing antibodies in cervical cancer and herpes-infected patients using local herpes simplex virus type 2. Int J Cancer. 1980; 25: 67-71.
14. Suryawanshi S, Huang X, Elishaev E, et al. Complement pathway is frequently altered in endometriosis and endometriosis-Associated ovarian cancer. Clin Cancer Res. 2014; 20: 6163-6174.
15. Nunez-Cruz S, Gimotty PA, Guerra MW, et al. Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012; 14: 994-1004.
16. Bjorge L, Stoiber H, Dierich MP, et al. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scand J Immunol. 2006; 63: 355-364.
17. Okroj M, Holmquist E, Nilsson E, et al. Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence. Cancer Immunol Immunother. 2015; 64: 467-478.
18. Qiu YM, Korteweg C, Chen ZS, et al. Immunoglobulin G expression and its colocalization with complement proteins in papillary thyroid cancer. Mod Pathol. 2012; 25: 36-45.
19. Piao C, Cai L, Qiu S, et al. Complement 5a enhances hepatic metastases of colon cancer via monocyte chemoattractant protein-1-mediated inflammatory cell infiltration. J Biol Chem. 2015; 290: 10667-10676.
20. Wilczek E, Rzepko R, Nowis D, et al. The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer. 2008; 122: 2030-2037.
21. Baatrup G, Qvist N, Junker A, et al. Activity and activation of the complement system in patients being operated on for cancer of the colon. Eur J Surg. 1994; 160: 503-510.
22. Wang H, Zhang D, Wu W, et al. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010; 58: 1121-1127.
23. Kang BW, Jeong JY, Chae YS, et al. Phosphorylated AMPactivated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2012; 70: 735-741.
24. Al-Moundhri MS, Al-Hadabi I, Al-Mawaly K, et al. Prognostic significance of cyclooxygenase-2, epidermal growth factor receptor 1, and microvascular density in gastric cancer. Med Oncol. 2012; 29: 1739-1747.
25. Fosbrink M, Niculescu F, Rus H. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res. 2005; 31: 37-46.
26. Barbano G, Cappa F, Prigione I, et al. Peritoneal mesothelial cells produce complement factors and express CD59 that inhibits C5b-9-mediated cell lysis. Adv Perit Dial. 1999; 15: 253-257.
27. Shirazi Y, McMorris FA, Shin ML. Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte x C6 glioma cell hybrids. J Immunol. 1989; 142: 4385-4391.
28. Cui TT, Chen Y, Knosel T, et al. Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol. 2011; 39: 161-168.
29. Kapitza E, Denkhaus D, zur Muhlen A, et al. Stratification of infant patients with medulloblastoma: genomics and biology complement histological classification. Brain Pathol. 2014; 24: 75-75.
30. Vlaicu SI, Tegla CA, Cudrici CD, et al. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res. 2013; 56: 109-121.
31. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010; 34: J276-J286.
32. Xu GL, Chen J, Yang F, et al. C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression. Hepatology. 2014; 60: 114-124.